NVAX250117P9500
- 0.83
- -0.32-27.83%
Novavax Newsroom
B.Riley Financial Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $22
Novavax's Strategic Partnerships and Pipeline Developments Drive Buy Rating With Promising Long-term Growth Potential
Novavax Analyst Ratings
H.C. Wainwright Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $19
B.Riley Financial Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $22
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Novavax (NVAX) and Veeva Systems (VEEV)
BioNTech Stock Has Been Hit Hard Since RFK Jr.'s Nomination. Why This Analyst Upgraded It. -- Barrons.com
B.Riley Financial Maintains Novavax(NVAX.US) With Buy Rating, Cuts Target Price to $22
B. Riley Adjusts Novavax Price Target to $22 From $26, Maintains Buy Rating
Strategic Transformation and Growth Prospects: Mayank Mamtani's Buy Rating on Novavax
Novavax Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Novavax, Maintains $19 Price Target
J.P. Morgan Maintains Novavax(NVAX.US) With Sell Rating, Maintains Target Price $9
Novavax's Market Share and Pipeline Uncertainties Lead to Sell Rating
BofA Securities Maintains Novavax(NVAX.US) With Hold Rating, Cuts Target Price to $12
H.C. Wainwright Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $19
HC Wainwright & Co. Reiterates Buy on Novavax, Maintains $19 Price Target
Novavax Analyst Ratings
Novavax Gains Competitive Edge With FDA Clearance and Strategic Collaborations, Earning Buy Rating
J.P. Morgan Maintains Novavax(NVAX.US) With Sell Rating, Maintains Target Price $9